SPAQ-CO™ dispersible

Guilin, a Fosum Pharma company

Product category
  • Seasonal malaria chemoprevention (sulfadoxine-pyrimethamine + amodiaquine)

Therapeutic indication
  • Seasonal malaria chemoprevention for children 3 to 59 months in eligible region

Dosing
  • Once daily for 3 days (amodiaquine) and one day (sulfadoxine-pyrimethamine), administered in monthly cycles for 4 months

Efficacy
  • 75% reduction in malaria episodes in pivotal trials

Key features
  • Recommended by WHO for the prevention of malaria in children in areas of high seasonal malaria transmission

Challenges
  • The sole prequalified supplier
  • Drug distribution to healthy subjects mainly via door-to-door campaigns
Status
  • First taste-masked dispersible SPAQ formulation prequalified by WHO
Next milestone
  • Country-led evaluation of expanded use of SPAQ in children from 6-10 years old 
  • Exploration of expanded duration of coverage in certain areas with a transmission period >4 months  
MMV Project Director
  • Dr André-Marie Tchouatieu